Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978332 | 1.00 | PTPN1 (0.32) | PTPN1MAPTPTPN2CDC25B | |
| Water SCHEMBL979696 | 0.99 | PTPN1 (0.31) | PTPN1 | |
| Water SCHEMBL4434601 | 0.99 | PTPN1 (0.31) | PTPN1 | |
| SCHEMBL4300408 | 0.87 | PTPN1 (0.31) | PTPN1 | |
| SCHEMBL976693 | 0.87 | PTPN1 (0.31) | PTPN1 | |
| SCHEMBL30122153 | 0.82 | PTPN1 (0.32) | PTPN1MAPTPTPN2CDC25B | |
| Water SCHEMBL980662 | 0.81 | HRH3 (0.38) | PTPN1PTPN2CDC25B | |
| SCHEMBL977047 | 0.79 | LMNA (0.38) | — | |
| SCHEMBL4300391 | 0.79 | LMNA (0.38) | — | |
| SCHEMBL17975545 | 0.78 | PTPN1 (0.32) | PTPN1PTPN2CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250148-B1 | CRYSTALLINE FORM OF CALCIUM-SALTS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACIDS AND METHODS OF USE | XENOPORT INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-8258179-B2 | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use | XENOPORT, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2250148-A2 | CRYSTALLINE FORM OF CALCIUM-SALTS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACIDS AND METHODS OF USE | XenoPort, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20090215809-A1 | CRYSTALLINE FORM OF A (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUG AND METHODS OF USE | XENOPORT, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2009094577-A2 | MESOPHASIC FORMS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUGS AND METHODS OF USE | XENOPORT, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094563-A2 | CRYSTALLINE FORM OF CALCIUM-SALTS OF (3S)-AMINOMETHYL-B-METHYL-HEXANOIC ACIDS AND METHODS OF USE | XENOPORT, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20090192222-A1 | MESOPHASIC FORMS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUGS AND METHODS OF USE | XENOPORT, INC. (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215809-A1 | CRYSTALLINE FORM OF A (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUG AND METHODS OF USE | HEXA, ADSL, CYP2S1 | PTPN1 2392/4885MAPT 2224/4885PTPN2 3226/4885 |
| US-20090192222-A1 | MESOPHASIC FORMS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUGS AND METHODS OF USE | SI, ACMSD, HMBS | PTPN1 1899/4885MAPT 3636/4885PTPN2 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.